Clinical Trial Update: Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial) [Phase 2]

View source ↗

Summary

Phase 2 trial results for talazoparib plus avelumab in STK11-mutant stage IV non-small cell lung cancer (LUNG-MAP trial) have been completed with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• BAVENCIO (AVELUMAB)
• Talzenna (talazoparib)

Snippet

Sponsor: SWOG Cancer Research Network | Conditions: Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2023-01-09